19 . January , 2019 - Saturday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Azacitidine

Big Image Pronouncation: (AZE-ah-SIGH-tih-deen)
Class: DNA demethylation agent

Trade Names:
Vidaza
- Powder for injection, lyophilized 100 mg

Mechanism of Action

Pharmacology

Believed to cause hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in bone marrow.

Pharmacokinetics

Absorption

Rapidly absorbed after subcutaneous administration; C max 750 ng/mL in 0.5 h. Subcutaneous bioavailability 89% compared with IV administration.

Distribution

Mean Vd is 76 L.

Elimination

Mean apparent subcutaneous Cl is 167 L/h and mean t ½ is 41 min. After subcutaneous administration, mean urinary excretion 50%. Mean elimination t ½ 4 h.

Indications and Usage

Treatment of myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.

Contraindications

Advanced malignant hepatic tumors; hypersensitivity to mannitol or azacitidine.

Dosage and Administration

Adults

Subcutaneous Recommended starting dose is 75 mg/m 2 daily for 7 days, every 4 wk. Premedicate patient for nausea and vomiting. Increase dose to 100 mg/m 2 if no beneficial effect seen after 2 treatment cycles and if no toxicity other than nausea and vomiting occur. Recommended that patients be treated for a minimum of 4 cycles. Treatment may be continued as long as patient continues to benefit.

Dosage Adjustments Based on Hematologic Laboratory Values
Adults

Subcutaneous For patients with WBC at least 3 × 10 9 /L, ANC at least 1.5 × 10 9 /L and platelets at least 75 × 10 9 /L at the start of treatment, adjust dose based on nadir counts for any given cycle as follows:

  • ANC less than 0.5 × 10 9 /L, platelets less than 25 × 10 9 /L administer 50% of dose in next course.
  • ANC 0.5 to 1.5 × 10 9 /L, platelets 25 to 50 × 10 9 /L administer 67% of dose in next course.
  • ANC greater than 1.5 × 10 9 /L, platelets greater than 50 × 10 9 /L administer 100% of dose in next course.
  • For patients with WBC less than 3 × 10 9 /L, ANC less than 1.5 × 10 9 /L, or platelets less than 75 × 10 9 /L at the start of treatment, base dose adjustments on nadir counts and bone marrow biopsy cellularity at time of nadir as follows, unless there is clear improvement in differentiation (percentage of mature granulocytes is higher and ANC is higher than at onset of course) at time of next cycle, in which case continue the dose of the current treatment.
  • WBC or platelet nadir percent decrease in counts from baseline is 50% to 75% and bone marrow biopsy cellularity at time of nadir is 30% to 60%, give 100% of dose in next course.
  • WBC or platelet nadir percent decrease in counts from baseline is 50% to 75% and bone marrow biopsy cellularity at time of nadir is 15% to 30%, give 50% of dose in next course.
  • WBC or platelet nadir percent decrease in counts from baseline is 50% to 75% and bone marrow biopsy cellularity at time of nadir is less than 15%, give 33% of dose in next course.
  • WBC or platelet nadir percent decrease in counts from baseline is greater than 75% and bone marrow biopsy cellularity at time of nadir is 30% to 60% give 75% of dose in next course.
  • WBC or platelet nadir percent decrease in counts from baseline is greater than 75% and bone marrow biopsy cellularity at time of nadir is 15% to 30% give 50% of dose in next course.
  • WBC or platelet nadir percent decrease in counts from baseline is greater than 75% and bone marrow biopsy cellularity at time of nadir is less than 15% give 33% of dose in next course.
  • If a nadir as defined above has occurred, give the next course of treatment 28 days after the start of the preceding course provided that both WBC and platelet counts are greater than 25% above the nadir and rising. If a greater than 25% increase above nadir is not seen by day 28, reassess counts every 7 days. If a 25% increase is not seen by day 42, treat the patient with 50% of the scheduled dose.
Dosage Adjustments Based on Renal Function and Serum Electrolytes
Adults

Subcutaneous If unexplained reductions in serum bicarbonate levels to less than 20 mEq/L occur, reduce dosage 50% on next course. If unexplained elevations of BUN or serum creatinine occur, delay the next cycle until values return to normal or baseline and reduce dose 50% on next treatment course.

General Advice

  • Reconstitute powder with 4 mL sterile water for injection. Inject diluent slowly into vial then invert vial 2 to 3 times and gently rotate until a uniform suspension is obtained. Resulting suspension contains 25 mg/mL of azacitidine.
  • Draw contents into syringe. Divide doses greater than 4 mL equally into 2 syringes.
  • Immediately prior to administration resuspend the contents by inverting syringe 2 to 3 times and gently rolling the syringe between the palms for 30 sec.
  • Rotate sites for each injection (eg, thigh, abdomen, upper arm). Give new injections at least 1 inch from an old site and never into areas where the site is tender, bruised, red, or hard.
  • Discard unused portions of vial. Do not save any unused portions for future use.

Storage/Stability

Store unopened vials at controlled room temperature (59° to 86°F). If not used immediately, reconstituted suspension may be held for up to 1 h at room temperature (77°F) but must be administered within 1 h of reconstitution. The reconstituted suspension may be refrigerated immediately and held in refrigerator (36° to 46°F) for up to 8 h. After removal from refrigerator, the suspension may be allowed to equilibrate to room temperature for up to 30 min.

Drug Interactions

None well documented.

Laboratory Test Interactions

None well documented.

Adverse Reactions

Cardiovascular

Cardiac murmur (10%); tachycardia (9%); hypotension (7%); atrial fibrillation, cardiac failure, CHF, cardio-pulmonary arrest, congestive cardiomyopathy, orthostatic hypotension (less than 5%).

CNS

Fatigue (36%); headache (22%); dizziness (19%); anxiety, aggravated fatigue, decreased appetite (13%); depression (12%); insomnia (11%); syncope (6%); hypoesthesia (5%); convulsions, intracranial hemorrhage, confusion (less than 5%).

Dermatologic

Petechiae (24%); erythema (17%); pallor (16%); skin lesion (15%); rash (14%); pruritus (12%); increased sweating (11%); night sweats (9%); urticaria (6%); skin nodule, dry skin (5%); pyoderma gangrenosum, pruritic rash, skin induration (less than 5%).

EENT

Pharyngitis (20%); epistaxis (16%); nasopharyngitis (15%); rhinorrhea (10%); nasal congestion (6%).

GI

Nausea (71%); vomiting (54%); diarrhea (36%); constipation (34%); anorexia (21%); abdominal pain (16%); abdominal tenderness (12%); upper abdominal pain (11%); gingival bleeding (10%); oral mucosal petechiae, stomatitis (8%); hemorrhoids, dyspepsia (7%); abdominal distention, loose stools (6%); mouth hemorrhage, dysphagia, tongue ulceration (5%); diverticulitis, GI hemorrhage, melena, perirectal abscess (less than 5%).

Genitourinary

Dysuria, UTI (8%); hematuria, loin pain, renal failure (less than 5%).

Hematologic-Lymphatic

Anemia (70%); thrombocytopenia (66%); leukopenia (48%); neutropenia (32%); febrile neutropenia (16%); lymphadenopathy (10%); hematoma (9%); aggravated anemia, postprocedural hemorrhage (6%); agranulocytosis, bone marrow depression, splenomegaly (less than 5%).

Hepatic

Cholecystitis (less than 5%).

Hypersensitivity

Anaphylactic shock, hypersensitivity (less than 5%).

Lab Tests

Hypokalemia (13%).

Local

Injection site erythema (35%); ecchymosis (31%); injection site pain (23%); injection site bruising or reaction (14%); injection site pruritus (7%); injection site granuloma, injection site pigmentation changes, injection site swelling (5%); catheter site hemorrhage (less than 5%).

Metabolic-Nutritional

Peripheral edema (19%); decreased weight (16%); pitting edema (15%); peripheral swelling (7%); dehydration (less than 5%).

Musculoskeletal

Arthralgia (22%); myalgia (16%); muscle cramps (6%); aggravated bone pain, muscle weakness, neck pain (less than 5%).

Respiratory

Cough (30%); dyspnea (29%); exertional dyspnea (14%); upper respiratory tract infection (13%); productive cough, crackles in lung, pneumonia (11%); wheezing, rales (9%); decreased breath sounds, rales (8%); pleural effusion, rhonchi (6%); exacerbated dyspnea, atelectasis, sinusitis (5%); hemoptysis, lung infiltration, pneumonitis, respiratory distress (less than 5%).

Miscellaneous

Pyrexia (52%); weakness (29%); rigors (26%); limb pain (20%); back pain, contusion (19%); chest pain (16%); pain, malaise (11%); herpes simplex (9%); cellulitis, lethargy (8%); transfusion reaction (7%); chest wall pain; postprocedural pain (5%); general physical health deterioration, systemic inflammatory response syndrome, limb abscess, bacterial infection, blastomycosis, Klebsiella sepsis, streptococcal pharyngitis, Klebsiella pneumonia, sepsis, staphylococcal bacteremia, staphylococcal infection, toxoplasmosis, leukemia cutis, cholecystectomy (less than 5%).

Precautions

Monitor

Renal function

Ensure that renal function is evaluated prior to starting therapy and before each cycle. If unexplained elevations in BUN or creatinine occur, delay next cycle until values return to normal or baseline, and reduce the dose 50% on the next treatment course.


Pregnancy

Category D .

Lactation

Undetermined.

Children

Safety and efficacy not established.

Elderly

Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function.

Renal Function

Monitor for toxicity because azacitidine and its metabolites are primarily excreted by the kidneys.

Hepatic Function

Use with caution.

Hematologic

Neutropenia and thrombocytopenia may occur; monitor CBC.

Renal abnormalities

Elevated serum creatinine, renal failure, and death may occur.

Skin/Mucus membranes

Avoid contact with skin and mucus membranes. If accidental skin contact occurs, wash thoroughly with soap and water. If mucus membrane contact occurs, flush thoroughly with water. If eye contact occurs, flush eyes using standard irrigation techniques.

Use in men

Advise men to use effective contraception during treatment.

Overdosage

Symptoms

Bone marrow suppression, diarrhea, nausea, vomiting.

Patient Information

  • Advise patient that medication will be prepared and administered by health care providers in a health care setting.
  • Review dosing schedule with patient.
  • Advise patient to immediately report any of the following to health care provider: rash; hives; difficulty breathing; fever, chills, or other signs of infection; unusual bleeding or bruising; pain, redness, or swelling at injection site.
  • Advise patient to report any of the following to health care provider: persistent nausea, vomiting or appetite loss; persistent or worsening general body weakness.
  • Caution men to use effective contraception during therapy.
  • Caution women of childbearing potential to avoid becoming pregnant during therapy.

Recent Drug Updates at DrugIndexOnline:





Antivenin, Black Widow Spider Antivenin, Black Widow Spider
Another commonly used name in the U.S. and Canada is antivenin ( Latrodectus mactans ) . Category Immunizing agent, passive Description Black widow spider antivenin belongs to a group of medicines known as immunizing agents. It is used to treat patients with serious symptoms caused by th more...

Chlorpheniramine/Codeine/Pseudoephedrine Liquid Chlorpheniramine/Codeine/Pseudoephedrine Liquid
Generic Name: Chlorpheniramine/Codeine/Pseudoephedrine Liquid (klor-fen-EER-a-meen/KOE-deen/sue-do-eh-FED-rin) Brand Name: Examples include Dihistine DH and Novahistine DHChlorpheniramine/Codeine/Pseudoephedrine Liquid is used for:Treating symptoms of the common cold, flu, or hay fever, and oth more...

Depo-Estradiol Depo-Estradiol
Some commonly used brand names are: In the U.S.— Alora 4 Climara 4 Congest 1 Delestrogen 4 Depo-Estradiol 4 Depogen 4 Estinyl 7 Estrace 4 Estraderm 4 Estragyn 5 5 Estragyn LA 5 4 Estrasorb 4 Estro-L.A. 4 Kestrone-5 5 Neo-Estrone 4 Menest 3 Ogen .625 6 Ogen 1.25 6 Ogen 2.5 6 Ortho-Est .625 more...

lactulose lactulose
Generic Name: lactulose (LACK too lohss) Brand Names: Cephulac, Chronulac, Constulose, Duphalac, Enulose What is lactulose? Lactulose is a type of sugar. It is broken down into mild acids in the colon (the end part of the intestinal tract). These acids draw water into the colon and there more...

Lorazepam (parenteral only) Lorazepam (parenteral only)
Some commonly used brand names are: In the U.S.— Alprazolam Intensol 1 Ativan 12 Dalmane 9 Diastat 7 Diazepam Intensol 7 Dizac 7 Doral 16 Halcion 18 Klonopin 5 Librium 3 Lorazepam Intensol 12 Niravam 1 Paxipam 10 ProSom 8 Restoril 17 Serax 14 Tranxene-SD 6 Tranxene-SD Half Strength 6 Tran more...

Mintezol Mintezol
Generic Name: Thiabendazole Chewable Tablet (thye-a-BEN-da-zole) Brand Name: MintezolMintezol is used for:Treating worm infections. It may also be used for other conditions as determined by your doctor. Mintezol is an anthelmintic. The exact way Mintezol works is unknown. It is thought to wor more...

Nilandron Nilandron
Generic Name: Nilutamide Dosage Form: Tablets Nilandron Description Nilandron® tablets contain nilutamide, a nonsteroidal, orally active antiandrogen having the chemical name 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione with the following structural formula: Nilu more...

Oxcarbazepine Suspension Oxcarbazepine Suspension
Generic Name: Oxcarbazepine Oral Suspension (ox-kar-BAZ-e-peen) Brand Name: TrileptalOxcarbazepine Suspension is used for:Treating certain type of seizures in patients with epilepsy. It may be used alone or with other medicines. It may also be used for other conditions as determined by your doct more...